No Data
No Data
Investors Still Aren't Entirely Convinced By Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) Earnings Despite 25% Price Jump
Despite an already strong run, Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329) shares have been powering on, with a gain of 25% in the last thirty days. Unfortunately, th
Da Ren Tang (600329): The Q1 results were generally in line with expectations, and quick price increases led to an increase in gross margin
Incident: The company released its 2024 quarterly report, 2024Q1. The company achieved operating income of 2,086 billion yuan, a year-on-year decrease of 3.19%; net profit to mother was 387 million yuan, a year-on-year decrease of 3.36%; net profit not attributable to mother
Tianjin Pharmaceutical's Q1 Profit, Revenue Fall 3%
Tianjin Pharmaceutical Da Ren Tang's (SHA:600329) attributable profit fell 3.4% year over year to 387.3 million yuan in the first quarter, according to a Tuesday filing with the Shanghai Stock Exchang
Express News | Da Ren Tang: Net profit from mother for the first quarter was 387 million yuan, down 3.36% year on year
Daren Tang (600329): High revenue growth in multiple treatment fields and overall profitability improvement
[Report: BL Guan_S key UM wants M element AR:y] On March 30, 2024, the company released its 2023 annual report. In 2023, the company achieved revenue of 8.222 billion yuan (-0.33%)
Traditional Chinese medicine stocks strengthened independently. At one point, Hanson Pharmaceuticals hit the market. Ma Yinglong rose by more than 6%, and China Resources rose by more than 5%, followed by Daren Tang and Fangsheng Pharmaceuticals.
Traditional Chinese medicine stocks strengthened independently. At one point, Hanson Pharmaceuticals hit the market. Ma Yinglong rose by more than 6%, and China Resources rose by more than 5%, followed by Daren Tang and Fangsheng Pharmaceuticals.
No Data